20
Jun
The Supreme Court decision last year on June 13, 2013 in Association of Molecular Pathology v. Myriad Genetics1 may have been a watershed moment for the biotechnology industry. So far the effects have been hard to detect, but don’t be fooled. The storm is still brewing.
At the center of the controversy in the Myriad case was Myriad’s so-called gene patents, which the Supreme Court struck down. The Court ruled that the isolation and identification of naturally occurring DNA sequences...